ritonavir (Q422618)

thiazol-5-ylmethyl (2S,3R,5R)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido(-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate

ritonavir (English)

18 November 2016

1 reference

thiazol-5-ylmethyl (2S,3S,5R)-3-hydroxy-5-((S)-2-(3-((2-isopropylthiazol-4-yl)methyl)-3-methylureido(-3-methylbutanamido)-1,6-diphenylhexan-2-ylcarbamate

inferred from InChI

1 reference

ritonavir (3R)-hydroxy epimer

inferred from InChI

1 reference

inferred from InChI

chemical formula

C₃₇H₄₈N₆O₅S₂

1 reference

ritonavir (English)

18 November 2016

CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O

1 reference

ritonavir (English)

18 November 2016

CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O

1 reference

https://www.whocc.no/atc_ddd_index/?code=J05AE03

ritonavir (English)

18 November 2016

1.2 gram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

nirmatrelvir/ritonavir

0 references

World Health Organisation international non-proprietary name

ritonavir (English)

1 reference

ritonavir (English)

medical condition treated

19 October 2016

2 references

13 December 2016

Drug Indications Extracted from FAERS

human immunodeficiency virus infectious disease

2 October 2018

1 reference

Drug Indications Extracted from FAERS

13 December 2016

1 reference

2 October 2018

COVID-19

1 reference

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

significant drug interaction

bosentan

1 reference

High-priority drug–drug interactions for use in electronic health records

carbamazepin

1 reference

High-priority drug–drug interactions for use in electronic health records

rifabutin

1 reference

High-priority drug–drug interactions for use in electronic health records

rifampicin

1 reference

High-priority drug–drug interactions for use in electronic health records

rifapentine

1 reference

High-priority drug–drug interactions for use in electronic health records

domperidone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ergotamine

ergotism

1 reference

A reference set of clinically relevant adverse drug-drug interactions

posaconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

simvastatin

rhabdomyolysis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

simvastatin

muscular disease

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rosuvastatin

rhabdomyolysis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rosuvastatin

muscular disease

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atorvastatin

rhabdomyolysis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atorvastatin

muscular disease

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

withdrawal symptom

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

buprenorphine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

buprenorphine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alfentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluticasone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fluticasone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dexamethasone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dexamethasone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prednisolone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prednisolone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prednisone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

prednisone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

triamcinolone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

triamcinolone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

budesonide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

budesonide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

verapamil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diltiazem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

thrombocytopenia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

leukopenia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fever

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diarrhea

1 reference

A reference set of clinically relevant adverse drug-drug interactions

anemia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nifedipine

sinus bradycardia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nifedipine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nifedipine

acute kidney injury

1 reference

A reference set of clinically relevant adverse drug-drug interactions

leukopenia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

anemia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

thrombocytopenia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Achor-Smith syndrom

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diarrhea

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

heart arrhythmia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

heart failure

1 reference

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cardiotoxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dasatinib monohydrate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

panobinostat

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sufentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eliglustat

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ivabradine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dabrafenib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

quetiapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vinblastine

neutropenia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vinblastine

Functional constipation

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vinblastine

peripheral neuropathy

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pazopanib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

midazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

midazolam

sedation complication

1 reference

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cardiotoxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tacrolimus

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Ketoconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

route of administration

oral administration

0 references

legal status (medicine)

boxed warning

1 reference

reference URL

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

Australian pregnancy category B3

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category B

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category C

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Ritonavir

last update

1 September 2017

subject has role

xenobiotic-transporting ATPase inhibitor

1 reference

5 March 2018

HIV protease inhibitors

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

D019438

cytochrome P-450 CYP3A inhibitors

15 March 2018

1 reference

CAS COVID-19 Anti-Viral Candidate Compounds

Medical Subject Headings

15 March 2018

0 references

1 reference

2 references

Ritonavir

0 references

catalog

0 references

Identifiers

InChI

InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

1 reference

ritonavir (English)

18 November 2016

2 references

ritonavir (English)

18 November 2016

ChEBI release 2020-09-01

CAS Registry Number

155213-67-5

2 references

Global Substance Registration System

UNII

O3J8G9O825

ritonavir (English)

18 November 2016

https://commonchemistry.cas.org/detail?cas_rn=155213-67-5

10 April 2021

1 reference

Ritonavir (English)

18 November 2016

2 references

ritonavir (English)

18 November 2016

InChIKey

Reaxys registry number

768009

1 reference

ritonavir (English)

19 October 2016

mapping relation type

2 references

RITONAVIR (English)

18 November 2016

International Chemical Identifier

InChI

InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

1 reference

RITONAVIR (English)

18 November 2016

2 references

inferred from InChIKey

InChIKey

Cambridge Structural Database

1 reference

1 reference

10 January 2023

1 reference

Cambridge Structural Database

10 January 2023

MSBNK-Athens_Univ-AU219201

InChIKey match

MassBank accession ID

0 references

MSBNK-Athens_Univ-AU219202

0 references

MSBNK-Athens_Univ-AU219203

0 references

MSBNK-Athens_Univ-AU219204

0 references

MSBNK-Athens_Univ-AU219205

0 references

MSBNK-Athens_Univ-AU219207

0 references

MSBNK-Athens_Univ-AU219208

0 references

MSBNK-Athens_Univ-AU219209

0 references

MSBNK-Athens_Univ-AU219210

0 references

MSBNK-Athens_Univ-AU219211

0 references

MSBNK-Athens_Univ-AU219230

0 references

MSBNK-Athens_Univ-AU219231

0 references

MSBNK-Athens_Univ-AU219232

0 references

MSBNK-Athens_Univ-AU219233

0 references

MSBNK-Athens_Univ-AU219234

0 references

MSBNK-Waters-WA001498

0 references

MSBNK-Waters-WA001499

0 references

MSBNK-Waters-WA001500

0 references

MSBNK-Waters-WA001501

0 references

MSBNK-Waters-WA001502

0 references

MSBNK-Waters-WA001503

0 references

SPLASH

splash10-0002-1890100200-749c81b805f598dabd2c

0 references

splash10-000t-4971130000-6788130f61c4c61a395b

0 references

splash10-01dj-0490400400-51a0b80eb0fdf1a6ade4

0 references

HSDB ID

7160

1 reference

Hazardous Substances Data Bank

28 October 2019

RITONAVIR (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

InChIKey

DSSTOX compound identifier

0 references

0 references

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.125.710

27 December 2018

ECHA Substance Infocard ID

1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate (English)

quotation

CAS no.: 155213-67-5 (English)

100.125.710

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.125.710

27 December 2018

1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate (English)

quotation

CAS no.: 155213-67-5 (English)

1 reference